KUALA LUMPUR: The National Pharmaceutical Regulatory Agency (NPRA) of the Ministry of Health has so far not received any documentation from Pfizer on the registration and testing of Covid-19 vaccine evaluation, said Health Director General Tan Sri Dr Noor Hisham Abdullah.
He said the ministry did not have direct information on whether there had been any problems with the supply of the vaccine, which were reported by a foreign media agency.
“However, the Ministry of Health will monitor the development of the Pfizer Covid-19 vaccine and get more information on the matter.
“The ministry will keep the public informed of developments from time to time,” he said in a statement today.
On 4 December, Dr Noors Hishams commented on a Reuters report which said, among other things, that the pharmaceutical company might not be able to meet its 2020 vaccine production target due to a shortage of raw materials.
He said NPRA has a responsibility to ensure that all products are subject to an evaluation and testing process based on the principles of quality, safety and efficacy before being registered in the Malaysian market.
In addition, he said, NPRA also ensures that the quality, safety and efficacy of vaccines and authorized medicines are always guaranteed through a quality product monitoring program and pharmacovigilance. – Named